**CURRICULUM VITAE**

**Name: Arry Dieudonne, M.D.**

**Associate Professor of Pediatrics**

Office Address: Rutgers, The State University of New Jersey

RBHS New Jersey Medical School

Department of Pediatrics

Division of, Allergy, Immunology and Infectious Diseases

185 So. Orange Ave. - F508

Newark, New Jersey 07103

973-972-5216(Office)

973-972-6443 (Fax)

[dieudar@njms.rutgers.edu](mailto:dieudar@njms.rutgers.edu)

**Education:**

1. **Undergraduate**

# Our Lady College of Cap-Haitien

Cap-Haitien, Haiti

B.S., Biology Oct. 1960 – June 1974

1. **Professional**

# State University School of Medicine

Haiti

M.D. Oct. 1976 – June 1982

**Postdoctoral Training:**

**a. Internship and Residencies**

Bronx Lebanon Hospital Center

Bronx, New York

Pediatric Resident July 1989 – June 1992

Sanatorium de Port-au-Prince

Port-au-Prince, Haiti

Surgery Resident Oct. 1983 – Sept. 1986

**b. Fellow**

University of Medicine and Dentistry of New Jersey

Newark, New Jersey

Pediatric Infectious Diseases and Immunology July 1992 – June 1994

The Wharton School-University of Pennsylvania

Philadelphia, PA

Development Management for Physician Executives 1997

**Military:**

None

**Licensure:**

New Jersey Medical License - #058733 Expire: 06/30/17

New York State Medical License - #189972 Expire: 09/30/16

**Certification:**

1. Specialty Board:

# New Jersey - Pediatrics Certified: 1993 - 2000

Recert: 2000 - 2007

: 2007 - 2014

1. Subspecialty Board

Pediatric Infectious Diseases Certified: 2003 - 2013

**Narcotics Certification:**

a. New Jersey CDS #D059110E Expiration: 10/31/16

b. New Jersey DEA #BD3549269 Expiration: 06/30/17

c. New York DEA #BD9876953 Expiration: 06/30/17

**Medicare #** D180139 **Medicaid #** 6690700 **UPIN #** G15612  **NPI #** 1649349333

**RBHS-NJMS APPOINTMENTS:**

**Rutgers New Jersey Medical School**

Department of Pediatrics

Associate Professor of Pediatrics July 2006 – Present

Assistant Professor of Pediatric July 1994 – June 2006

College of Notre Dame

Clinical Instructor in Biology Oct. 1974 – Sept. 1976

**HOSPITAL APPOINTMENTS:**

A **Hospital Appointments:**

François-Xavier Bagnoud Center for Children

University Hospital

Newark, NJ

Clinical Director Feb. 1997 – Present

B Department of Pediatrics

University of Medicine & Dentistry of New Jersey/University Hospital

Newark, New Jersey

Staff Physician July 1994 – Present

C Department of Pediatrics

Children’s Hospital of New Jersey/United Health Care

Newark, New Jersey

Attending July 1994 – Feb. 1997

**OTHER PROFESSIONAL POSITIONS AND MAJOR VISITING APPOINTMENTS:**

1. Lecturer

Medical Society of New Jersey

Trenton, New Jersey 2005

François-Xavier Bagnoud Haiti Project

In partnership with CDC & ITECH

Newark, NJ

Consultant 2005 – 2006

1. Government of Guyana

Minister of Health

National AIDS Program

Guyana 2004

1. Government of Haiti

Minister of Health

National AIDS Program

Haiti 2004

1. Medical Research Foundation

Port of Spain, Trinidad

Visiting Professor/Lecturer 2004

1. Rwanda MTCT-Plus Meeting

Kigali, Rwanda

Visiting Professor (Team Leader) 2003

1. Department of Pediatrics

Wyckoff Heights Hospital

Brooklyn, New York

Associate Medical Staff 1996 - 1998

1. Department of Pediatrics/Division of Allergy, Immunology & Infectious Diseases

St. Barnabas Medical Center

Livingston, New Jersey

Consulting Physician 1995 - 1998

1. François Xavier Bagnoud-Global Training Program/NPHRC

University of Medicine & Dentistry of New Jersey

Newark, New Jersey

Consulting Physician 1994 - Present

1. Department of Pediatrics

Bronx Lebanon Hospital Center

Bronx, New York

Attending Physician 1992 - Present

1. Lynbrook Diagnostic Laboratories

Oceanside, New York Technician 1986 – 1989

1. Public Health Agent Community Health

Grande Riviere du Nord, Haiti

Practitioner/Counselor 1982 – 1983

**Awards and Honors:**

Golden Apple Nomination 2015 & 2016

Travel Grant Recipient, National Pediatric & Infectious Diseases Society 1993 & 1994

Fellowship Award, ICAAC/IDSA 1993

Excellence Award Academic Achievement, State University Medicine,

Haiti 1982

**Membership on Board of Directors or Trustees:**

None

**Major Teaching Experience:**

1. **Lectures**

College of Notre Dame 1974 – 1976

University of Medicine & Dentistry of New Jersey

New Jersey Medical School

Department of Pediatrics

Infectious Diseases in Pediatrics 1992 - Present

1. **Research Training**

1. Postdoctoral Fellows

## Pediatric Infectious Disease Fellows

Division of Allergy, Immunology & Infectious Diseases

New Jersey Medical School 1992 - Present

1. **Pre-doctoral Students**

## None

1. **Instruction**

MTCT-Plus

François-Xavier Bagnoud Center

University of Medicine & Dentistry of New Jersey 2002 – 2004

Preceptor International Fellows

François Xavier Bagnoud Global Training Center

University of Medicine & Dentistry of New Jersey July1994 – Present

**Principal Clinical and Hospital Service Responsibilities:**

University Hospital

### Department of Pediatrics

Attending in Pediatrics, including ward rounds & teaching conferences 1994 - Present

Pediatric Infectious Diseases consultations (inpatient and outpatient services)

**Major Committee Assignments**:

**a. International**

Consultant, University Technical Assistance Project

Centers for Disease Control Global Division Bureau

François-Xavier Bagnoud Center – UTAP Grant 2002 - Present

**b. National**

Pediatric AIDS Clinical Trials Group

2002 - Present

1. **Medical School**

Clinical Director, François-Xavier Bagnoud Clinical Services 1997 – Present

# Chair, Clinical Faculty CORE Committee 1994 – Present

# Consultant, START Adolescent HIV Program 1994 – 1997

Consultant DAYAM 2014-Present

1. **Hospital**

# Pharmaceutical Committee 2004 – 2007

1. **Department**

# None

1. **Editorial Boards**

# None

1. **Ad Hoc Reviewer**

# Coventry Health Care, Inc. 2004

# 

**Memberships, Offices & Committee Assignments in Professional Societies:**

American Medical Association – Member 1992 - Present

American Academy of Pediatrics - Fellow 1990 - Present

Pediatric Infectious Disease Society - Member 1992 - Present

**Major Research Interests:**

Being a fellow in the early 90’s when opportunistic infections (cryptosporidiosis, atypical mycobacterial infections, *pneumocystis carinii* pneumonia) were the most common causes of death in the pediatric population with HIV has increased my interests in that field. My continuous involvement in training international fellows from all over the world in HIV care has opened a new field of interest in HIV treatment and prevention of transmission of HIV from mother to child.

**Grant History:**

**Principal Investigator:**

**2008 – 2016 (renewable) -** Pediatric HIV/AIDS Cohort Study (PHACS) Data and Operations Center (CDC)

**(a) 2015 – 2016 *AMP & AMP UP***

PI: Arry Dieudonne

Sub Award Number: 114074.1052.5042765

**Amount Awarded: $402,352**

*2008 – 2009 AMP & AMP UP*

PI: Arry Dieudonne

**Amount Awarded: $406,098**

*2009 – 2010 AMP & AMP UP*

PI: Arry Dieudonne

**Amount Awarded: $273,607**

*2010 – 2011 AMP & AMP UP*

PI: Arry Dieudonne

**Amount Awarded: $243,300**

*2011 – 2012 AMP & AMP UP*

PI: Arry Dieudonne

**Amount Awarded: $517,413**

*2012– 2013 AMP & AMP UP*

PI: Arry Dieudonne

**Amount Awarded: $337,376**

*2013– 2014 AMP & AMP UP*

PI: Arry Dieudonne

**Amount Awarded: $432,675**

*2014 – 2015 AMP & AMP UP*

PI: Arry Dieudonne

**Amount Awarded: $384,784**

***Total for Amp & Amp Up - $2,997,605***

**(b) 2015 - 2016 *SMARRT***

PI: Arry Dieudonne

Sub Award Number: 114074.1054.5042767

**Amount Awarded**: **$294,193**

*2008 – 2009 SMARRT*

PI: Arry Dieudonne

**Amount Awarded: $272,071**

*2009 – 2010 SMARRT*

PI: Arry Dieudonne

**Amount Awarded: $171,504**

*2010– 2011 SMARRT*

PI: Arry Dieudonne

**Amount Awarded: $172,375**

*2011 – 2012 SMARRT*

PI: Arry Dieudonne

**Amount Awarded: $231,011**

*2012 – 2013 SMARRT*

PI: Arry Dieudonne

**Amount Awarded: $301,883**

*2013 – 2014 SMARRT*

PI: Arry Dieudonne

**Amount Awarded: $284,463**

*2014 – 2015 SMARRT*

PI: Arry Dieudonne

**Amount Awarded: $283,112**

***Total for SMARRT - $2,010,612***

**2014-2015 University of Miami [***SMAART***]**

PI: Arry Dieudonne

**Amount Awarded: 18,300**

**2007 – 2014: (Pediatric Investigator) Internal Maternal Pediatric Adolescents AIDS Clinical Trials**

**Group** *(IMPAACT))*

*Clinical Research Site (CRS} Leader*

PI: James Oleske

**Total amount awarded: $12,000,000**

**2006 – 2010 (renewable):** Longitudinal Epidemiologic Study to Gain Insight into HIV and AIDS in Children and Youth (LEGACY), a multi-site study in collaboration with Centers for Disease Control and Prevention (CDC)

**Direct = $74,411 Indirect = $41,298**

**Total amount awarded: $115,709**

**2003 – 2004**: Cyril Ross Nursery International Program

Children Affected by AIDS Foundation (CAAF)

**Direct = $18,182 Indirect = $1,818**

**Total amount awarded: $20,000**

**2000 – Present:** US SUSTIVA Oral Liquid Expanded Access Program

Parexel International Corporation

**No funding associated with this study.**

**Co-Investigator:**

**2003 – 2006**: Fogerty International Research Collaboration

HIV Related Immunologic Assay/Validation in Burkina Faso

PI: Thomas Denny

**Direct = $96,000 Indirect = $24,960**

**Total amount awarded: $120,960**

**2001 – 2007:** National Institutes of Health

New Jersey Pediatric AIDS Clinical Trials Consortium

PI: Paul Palumbo

**Direct = $6,087,928 Indirect = $2,729,624**

**Total amount awarded: $8,817,552**

**2002 – 2003:** MTCT-Plus: Education & Training Initiative

Mailman School of Public Health & Columbia University

PI: Mary Boland

**Direct = $430,247 Indirect $ 34,420**

**Total amount awarded: $700,000**

**1997 – 2000**: National Institutes of Health

New Jersey Pediatric AIDS Clinical Trials Consortium

PI: Paul Palumbo

**Direct = $2,976,210 Indirect = $1,229,883**

**Total amount awarded: $4,206,093**

**MAJOR ADMINISTRATIVE RESPONSIBILITIES:**

None

**PRIVATE PRACTICE**

None

**ARTICLES**

* 01 Purswani MU, Karalius B, Yao TJ, Schmid DS, Burchett SK, Siberry GK, Patel K, Van Dyke RB, Yogev R; Pediatric HIV/AIDS Cohort Study (PHACS); Pediatric HIV/AIDS Cohort Study PHACS. Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection. Clin Infect Dis. 2016 Jan 1;62(1):106-14. PMID: 26385992
* 02 Nichols SL, Brummel SS, Smith RA, Garvie PA, Hunter SJ, Malee KM, Kammerer BL, Wilkins ML, Rutstein R, Tassiopoulos K, Chernoff MC, Mellins CA; Pediatric HIV/AIDS Cohort Study. Executive Functioning in Children and Adolescents With Perinatal HIV Infection. Pediatr Infect Dis J. 2015 Sep;34(9):969-75. PMID: 26376309
* 03 Mirani G, Williams PL, Chernoff M, Abzug MJ, Levin MJ, Seage GR 3rd, Oleske JM, Purswani MU, Hazra R, Traite S, Zimmer B, Van Dyke RB; IMPAACT P1074 Study Team. Changing Trends in Complications and Mortality Rates Among US Youth and Young Adults With HIV Infection in the Era of Combination Antiretroviral Therapy. Clin Infec Dis. 2015Dec 15;61(12):1850-61. PMID: 26270680.
* 04 Marsit CJ, Brummel SS, Kacanek D, Seage GR 3rd, Spector SA, Armstrong DA, Lester BM, Rich K; Pediatric HIV/AIDS Cohort Studies Network. Infant peripheral blood repetitive element hypomethylation associated with antiretroviral therapy in utero. Epigenetics. 2015;10(8):708-16. PMID: 26067216
* 05. Siberry GK, Patel K, Bellini W, Karalius B, Purswani M, Burchett SK, Meyer WA 33rd, Sowers SB, Ellis A, Van Dyke RB; Pediatric HIV AIDS Cohort Study (PHACS); Pediatric HIV AIDS Cohort Study PHACS. Immunity to Measles, Mumps and Rubella in US children with Perinatal HIV Infection or Perinatal HIV Exposure without Infection*.* Clin Infect Dis. 2015 Jun 9 PMID: 26060291

* 06. Kapetanovic S, Aaron L, Montepiedra G, Anthony P, Thuvamontolrat K, Pahwa S, Burchett S, Weinberg A, Kovacs A; Pediatric AIDS Clinical Trials Group Protocol 366. Effect of cytomegalovirus co-infection on normalization of selected T-cell subsets in children with perinatally acquired HIV infection treated with combination antiretroviral therapy. PloS One. 2015 Mar 20;10(3):e0120474. Doi:10.1371/journal.pone. 012074.eCollection 2015. PMID: 25794163.
* 07. Torre P 3rd, Yao TJ, Zeldow B, Williams P, Hoffman HJ, Sibery GK; Pediatric HIV/AIDS cohort Study (PHACS). Distortion product otoacoustic emission data in perinatally HIV-infected and HIV-exposed but uninfected childen and adolescents in the Pediatric HIV/AIDS Cohort Study Pediatr Infect Dis J. 2015 Mar;34(3):276-8. PMID: 25742077.
* 08. Crowell CS, HUO Y, Tassiopoulos K, Malee KM, Yogev R, Hazra R, Rutstein RM, Nichols SL, Smith RA, Williams PL, Oleske J, Muller WJ; PACTG 219C Study Team and the Pediatrics HIV/AIDS Cohort Study (PHACS). Early viral suppression improves neurocognitive outcomes in HIV-infected children. AIDS. 2015 Jan 28;29(3):295-304. PMID: 25686678
* 09. Rough K, Tassiopoulos K, Kacanek D, Griner R, Yogev R, Rich KC, Seage GR 3rd; Pediatric HIV/AIDS Cohort Study. Dramatic decline in substance use by HIV-infected pregnant women in the United States from 1990 to 2012. AIDS.2015 Jan 2:29(1):17-23.
* 10. Lipshultz SE, Williams PL, Zeldow B, Wilkinson JD, Rich KC, Van Dye RB, Seage GR 3rd, Dooley LB, Kaltman JR, Siberry GK, Mofenson LM, Shearer WT, Colan SD; Pediatric HIV/AIDS Cohort Study (PHACS). Cardia effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers. AIDS. 2015 Jan 2;29(1):91-100, PMID: 25562493.
* 11. Williams PL, Crain MJ, Yildirim C, Hazra R, Van Dyke RB, Rich K, Read JS, Stuard E, Rathore M, Mendez HA, Watts DH; Pediatric HIV/AIDS Cohort Study. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants: JAMA Pediatr 2015 Jan; 169(1):48-55. Jamapediatrics.2014.1889. PMID: 25383770.
* 12. Rutstein RM, Samson P, Fenton T, Fletcher Cv, Kiser JJ, Mofenson LM, Smith E, Graham B, Mathew M, Aldrovani G; PACTG 1020A Study Team. Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: The Pediatric AIDS Clinical Trials Group Protocol 1020A. Pediatr Infect Dis J. 2015 Feb;34(2):162-7. PMID: 25232777.
* 13. Mitchell CD, Chernoff MC, Seage GR 3rd, Purswani MU, Spiegel HM, Zilleruelo G, Abitbol C, Heckman B, Ponce CB, Oleske JM; IMPAACT 219/219C Study Team [Predictors of resolution and persistence of renal laboratory abnormalities in pediatric HIV infection.](http://www.ncbi.nlm.nih.gov/pubmed/25149850) Pediatr Nephrol. 2015 Jan;30(1):153-65 PMID 25149850.
* 14. Nozyce ML, Huo Y, Williams PL, Kapetanovic S, Hazra R, Nichols S, Hunter S, Smith R, Seage GR 3rd, Sirois PA; Pediatric HIVAIDS Cohort Study. [Safety of in utero and neonatal antiretroviral exposure: cognitive and academic outcomes in HIV-exposed, uninfected children 5-13 years of age.](http://www.ncbi.nlm.nih.gov/pubmed/25361407) Pediatr Infect Dis J. 2014 Nov;33(11):1128-33. PMID 25361407
* 15. Garvie PA, Zeldow B, Malee K, Nichols SL, Smith RA, Wilkins ML, Williams PL; Pediatric

HIVAIDS Cohort Study (PHACS). [Discordance of cognitive and academic achievement outcomes in youth with perinatal HIV exposure.](http://www.ncbi.nlm.nih.gov/pubmed/25361033) Pediatr Infect Dis J. 2014 Sep;33(9):e232-8. PMID 25361033

* 16. Nesheim SR, Hardnett F, Wheeling JT, Siberry GK, Paul ME, Emmanuel P, Bohannon B, Dominguez K; LEGACY Consortium. Incidence of opportunistic illness before and after initiation of highly active antiretroviral therapy in children. Pediatr Infect Dis J. 2013 Oct; 32(10):1089-95; PMID: 24067552
* 17. [Rice ML](http://www.ncbi.nlm.nih.gov/pubmed?term=Rice%20ML%5BAuthor%5D&cauthor=true&cauthor_uid=24067563), [Zeldow B](http://www.ncbi.nlm.nih.gov/pubmed?term=Zeldow%20B%5BAuthor%5D&cauthor=true&cauthor_uid=24067563), [Siberry GK](http://www.ncbi.nlm.nih.gov/pubmed?term=Siberry%20GK%5BAuthor%5D&cauthor=true&cauthor_uid=24067563), [Purswani M](http://www.ncbi.nlm.nih.gov/pubmed?term=Purswani%20M%5BAuthor%5D&cauthor=true&cauthor_uid=24067563), [Malee K](http://www.ncbi.nlm.nih.gov/pubmed?term=Malee%20K%5BAuthor%5D&cauthor=true&cauthor_uid=24067563), [Hoffman HJ](http://www.ncbi.nlm.nih.gov/pubmed?term=Hoffman%20HJ%5BAuthor%5D&cauthor=true&cauthor_uid=24067563), [Frederick T](http://www.ncbi.nlm.nih.gov/pubmed?term=Frederick%20T%5BAuthor%5D&cauthor=true&cauthor_uid=24067563), [Buchanan A](http://www.ncbi.nlm.nih.gov/pubmed?term=Buchanan%20A%5BAuthor%5D&cauthor=true&cauthor_uid=24067563), [Sirois PA](http://www.ncbi.nlm.nih.gov/pubmed?term=Sirois%20PA%5BAuthor%5D&cauthor=true&cauthor_uid=24067563), [Allison SM](http://www.ncbi.nlm.nih.gov/pubmed?term=Allison%20SM%5BAuthor%5D&cauthor=true&cauthor_uid=24067563), [Williams PL](http://www.ncbi.nlm.nih.gov/pubmed?term=Williams%20PL%5BAuthor%5D&cauthor=true&cauthor_uid=24067563); [Pediatric HIVAIDS Cohort Study (PHACS)](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Pediatric%20HIVAIDS%20Cohort%20Study%20(PHACS)%22%5BCorporate%20Author%5D). Evaluation of risk for late language emergence after in utero antiretroviral Drug exposure in HIV-exposed uninfected infants. *Pediatr Infect Dis J*. 2013 Oct;32(10):e406-13.PMID: 24067563
* 18. Neely M, Rutstein R, Del Bianco G, Heresi G, Barton T, Wiznia A, Wiegand R, Wheeling T, Bohannon B, Dominguez K; LEGACY Consortium. Use of nucleoside Reverse transcriptase inhibitor-only regimens in HIV-infected children and adolescents. *Pediatr Infect Dis J.* 2013 Sep;32(9):e370-6. PMID: 24008749.
* 19. Sharma TS, Jacobson DL, Anderson L, Gerschenson M, Van Dyke RB, McFarland EJ, Miller TL: Pediatric HIV/AIDS Cohort Study (PHACS). Short communication: The Relationship between mitochondrial dysfunction and insulin resistance in HIV-infected children receiving antiretroviral therapy. *AIDS Res Hum Retroviruses.* 2013 Sep;29(9):1211-7. PMID: 23742635.
* 20. [Williams PL](http://www.ncbi.nlm.nih.gov/pubmed?term=Williams%20PL%5BAuthor%5D&cauthor=true&cauthor_uid=24145244), [Abzug MJ](http://www.ncbi.nlm.nih.gov/pubmed?term=Abzug%20MJ%5BAuthor%5D&cauthor=true&cauthor_uid=24145244), [Jacobson DL](http://www.ncbi.nlm.nih.gov/pubmed?term=Jacobson%20DL%5BAuthor%5D&cauthor=true&cauthor_uid=24145244), [Wang J](http://www.ncbi.nlm.nih.gov/pubmed?term=Wang%20J%5BAuthor%5D&cauthor=true&cauthor_uid=24145244), [Van Dyke RB](http://www.ncbi.nlm.nih.gov/pubmed?term=Van%20Dyke%20RB%5BAuthor%5D&cauthor=true&cauthor_uid=24145244), [Hazra R](http://www.ncbi.nlm.nih.gov/pubmed?term=Hazra%20R%5BAuthor%5D&cauthor=true&cauthor_uid=24145244), [Patel K](http://www.ncbi.nlm.nih.gov/pubmed?term=Patel%20K%5BAuthor%5D&cauthor=true&cauthor_uid=24145244), [Dimeglio LA](http://www.ncbi.nlm.nih.gov/pubmed?term=Dimeglio%20LA%5BAuthor%5D&cauthor=true&cauthor_uid=24145244), [Silio M](http://www.ncbi.nlm.nih.gov/pubmed?term=Silio%20M%5BAuthor%5D&cauthor=true&cauthor_uid=24145244), [Borkowsky W](http://www.ncbi.nlm.nih.gov/pubmed?term=Borkowsky%20W%5BAuthor%5D&cauthor=true&cauthor_uid=24145244), [Seage GR 3rd](http://www.ncbi.nlm.nih.gov/pubmed?term=Seage%20GR%203rd%5BAuthor%5D&cauthor=true&cauthor_uid=24145244), [Oleske JM](http://www.ncbi.nlm.nih.gov/pubmed?term=Oleske%20JM%5BAuthor%5D&cauthor=true&cauthor_uid=24145244), [Geffner ME](http://www.ncbi.nlm.nih.gov/pubmed?term=Geffner%20ME%5BAuthor%5D&cauthor=true&cauthor_uid=24145244); [International Maternal Pediatric and Adolescent AIDS Clinical Trials P219219C Study and the Pediatric HIVAIDS Cohort Study](http://www.ncbi.nlm.nih.gov/pubmed?term=International%20Maternal%20Pediatric%20and%20Adolescent%20AIDS%20Clinical%20Trials%20P219219C%20Study%20and%20the%20Pediatric%20HIVAIDS%20Cohort%20Study%5BCorporate%20Author%5D). Pubertal onset in children with perinatal HIV infection in the era of combination antiretroviral treatment.[*AIDS.*](http://www.ncbi.nlm.nih.gov/pubmed?term=International%20Maternal%20Pediatric%20and%20Adolescent%20AIDS%20Clinical%20Trials%20P219219C%20Study%20and%20the%20Pediatric%20HIVAIDS%20Cohort%20Study%5BCorporate%20Author%5D) 2013 Jul 31; 27(12): 1959-70. doi: 10.1097
* 21. Lipshultz SE, Williams PL, Wilkinson JD, Leister EC, Van Duke RB, Shearer WT, Rich KC, Hazra R, Kaltman JR, Jacoson DL, Dooley LB, Scott G, Raideau N, Colan DS; Pediatric HIV/AIDS Cohort Study (PHACS). Cardiac status of children infected with Human immunodeficiency virus who are receiving long-term combination antiretroviral Therapy: results from the Adolescent Master Protocol of the Multicenter Pediatric HIV/AIDS Cohort Study *JAMA Pediatr.* 2013 Jun;167(6):520-7 doi: 10.1001/jama pediatrics. 2013.1206. PMID: 23608879
* 22. Himes SK, Scheidweiler KB, Tassiopoulos K, Kacanek D, Hazra R, Rich K, HuestisMA; Pediatric HIV/AIDS Cohort Study. Development and validation of the first liquid Chromatography-tandem mass spectrometry assay for simultaneous quantification of Antiretrovirals in meconium. *Anal Chem.* 2013 Feb 5;85(3):1896-904; doi: 10.102/ac303188j. Epub 2014 Jan 14. PMID 23256731
* 23. Wilkinson JD, Williams PL, Leister E, Zeldow B, Shearer WT, Colan DS, Siberry GK, Dooley LB, Scott G, Rich KC, Lipshultz SE; Pediatric HIV/AIDS Cohort Study(PHACS) Cardia biomarkers in HIV-exposed uninfected children. *AIDS.* 2013 Apr 24;27(7):1099-108. Doi: 10.1097/QAD. Ob013e32835cf21c. PMID 23211773
* 24. Watts DH, Williams PL, Kacanek D, Griner R, Rich K, Hazra R, Mofenson LM, Mendez HA; Pediatric HIV/AIDS Cohort Study. Combination antiretroviral use and preterm birth. *J Infect Dis.* 2013 Feb 15;207(4):612-21. Doi. 10.1093/infdis/jis728.Epub 2012 Nov 29th.PMID 23204173.
* 25. Tassiopoulos K, Moscicki AB, Mellins C, Kacanek D, Malee K, Allison S, Hazra R, Siberry GK, Smith R, Paul M, Van Dyke RB, Seage GR 3rd; Pediatric HIV/AIDS Cohort Study. Sexual risk behavior among youth with perinatal HIV infection in the United States; predictors and implications for intervention development. *Clin Infect Dis.*2013 Jan;56(2):283-90. Doi: 10.1093/cid/cis816. Epub 2012 Nov 7. PMID 23139252
* 26. DiMeglio LA, Wang J, Siberry GK, Miller TL, Geffner ME, Hazra R, Borkowsky W, Chen JS, Dooley L, Patel K, Van Dyke RB, Fielding RA, Gurmu Y, Jacobson DL; Pediatric HIV/AIDS Cohort Study (PHACS). Bone mineral density in children and adolescents with perinatal HIV infection. *AIDS:* 2013 Jan 4;27(2):211-20. doi.10.1097/QAD.ob013e32835a9b80. PMID 23032412
* 27. Smith R, Chernoff M, Williams PL, Malee KM, Sirois PA, Kammerer B, Wilkins M,Nichois S, Mellins C, Usitalo A, Garvie P, Rutstein R. Pediatric HIV/AIDS Cohort Study (PHACS) Team. The Impact of HIV severity on cognitive and adaptive functioning during childhood & *a*dolescence *Pediatr Infect Dis J.* 2012 Jun;31(6):592-8.
* 28. Torre P 3rd, Zeldow B, Hoffman HJ, Buchanan A, Siberry GK, Rice M, Sirois PA, Williams PL; Pediatric HIV/AIDS Cohort Study. Pediatric HIV/AIDs Cohort Study*.* Hearing loss n perinatally HIV-infected and HIV-exposed but uninfected children and adolescents*. Pediatr Infect Dis J.* 2012 Aug;31(8):

835-41.

* 29. Williams PL, Seage GR 3rd, Van Dyke R, Siberry GK, Griner R, Tassiopoulos K, Yildirim C, Read JS, Huo Y,Hazra R, Jacobson DL, Mofenson LM, Rich K; Pediatric HIV/AIDS Cohort Study. A trigger-based design for evaluating the safety of in utero Antiretroviral exposure in uninfected children of human

immunodeficiency virus-infected mothers. *Am J Epidemiol,* 2012 May 1;175(9):950-61.

* 30. Siberry GK, Williams PL, Mendez H, Seage GR 3rd, Jacobson DL, Hazra R, Rich KC, Griner R, Tassiopoulos K, Kacanek D, Mofenson LM, Miller T, DiMeglio LA, Watts DH; Pediatric HIV/AIDS Cohort Study (PHACS). Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.  *AIDS* 2012 Jun 1;26(9):1151-9.
* 31. Miller TI, Borkowsky W, DiMeglio LA, Doolery L, Geffner ME, Hazra R, McFarland EJ, Mendez AJ, Patel K, Siberry GK, Van Dyke RB, Worrell CJ, Jacobson DL; Pediatric HIV/AIDS Cohort Study (PHACS), Shearer W, Cooper N, Harris L, Purswani M, Baig M, Clintron A, Puga A, Navarro S, Patton d, Burchett S, Karthas N, Kammerer B, Yogev R, Malee K, Hunter S, Cagwin E, Wiznia A, Burey M, Nozyce M, Chen J, Gobs E, Grant M, Knapp K, Allison K, Garvie P, Acevedo-Flores M, Rios H, Olivera v, Silio M, Borne C, Sirois P, Spector S, Norris K, Nichols S, McGarland E, Barr E, Chambers C, Watson D, Messenger N, Belanger R, Dieudonne A, Bettica L, Adubato S, Scott G, Himic L, Willen E. Metabolic abnormalities and viral replication are associated with Biomarkers of vascular dysfunction in HIV-infected children. *HIV Med.,* 2012 May;13(5):264-75. Epub 2011 Dec.4.
* 32. Setse R, Siberry GK, Moss WJ, Gravitt P, Wheeling T, bohannon B, Dominguez K, Legacy Consortium Cervical pap screening cytological abnormalities among HIV-infected adolescents in the LEGACY cohort. *J Pediatr Adolesc Gynecol* 2012 Feb;25(1):27-34. Epub 2011 Nov 16.
* 33. Crain MJ, Williams PL, Griner R, Tassiopoulos K, Read JS, Mofenson LM, Rich KC Pediatric HIV/AIDS Cohort Study. Point-of-care capillary blood lactate measurements in Utero exposure to human immunodeficiency virus and antiretroviral medications. *Pediatr Infect Dis J.,* 2011

Dec; 30(12):1069-74.

* 34. Jacobson DL, Patel K, Siberry GK, Van dyke R, DiMeglio LA, Geffner ME, Chen JS,

McFarland EJ, Borkowsky W, Silio M, Fielding RA, Siminski S, Miller TL; Pediatric HIV/AIDS

Cohort Study. Body fat distribution in perinatally HIV-infected and HIV-Exposed but uninfected

children in the era of highly active antiretroviral therapy:Outcomes from the Pediatric HIV/AIDS

Cohort Study. *AM J Clin Nutr.* 2011 Dec;94(6):1485-95. Epub 2011 Nov 2.

* 35. Geffner ME, Patel K, Miller TL, Hazra R, Silio M., Van Dyke RB, Borkowsky W., Worrell C., DiMeglio LA., Jacobson DL., Pediatric HIV/AIDS cohort Study. Factors associated with insulin resistance among children and adolescents perinatally infected with HIV-1 in the pediatric HIV/AIDS cohort study. *Horm Res Paediatr.*2011;76(6): 386-91. Epub 2011 Oct 26.
* 36. Mellins CA, Tassiopoulos K, Malee K, Moscicki AB, Patton D, Smith R, Usitalo A, Allison SM, Van Dyke R, Dieudonne, A Seage GR 3rd; Pediatric HIV/AIDS Cohort 777 Study. Behavioral health risks in perinatally HIV-exposed youth: co-occurrence of sexual and drug use behavior, mental health problems, and non-adherence to antiretroviral treatment. *AIDS Patient Care STDS*.2011 Jul; 25(7):413-22. Epub 2011May 5.
* 37. Griner R, Williams PL, Read JS, Seage GR 3rd, Crain M, Yogev R, Hazra R, Rich K; **Pediatric HIV/AIDS Cohort Study**. In utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States. *AIDS Patient Care STDS.* 2011 Jul;25(7):385-94. Epub 2011

Jun 10.

* 38. Flynn PM, Mirochnick M, Shapiro DE, Bardeguez A, Rodman J, Robbins B, Huang S, Fiscus SA, Van Rompay KK, Rooney JF, Kearney B, Mofenson LM, Watts DH, Jean-Philippe P, Heckman B, Thorpe E Jr, Cotter A, Purswani M; **PACTG 394 Study Team**.Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.Antimicrob Agents Chemother. 2011 Dec;55(12):5914-22. Epub 2011 Sep 6.
* 39. Kapetanovic S, Wiegand RE, Dominguez K, Blumberg D, Bohannon B, Wheeling J, Rutstein R; LEGACY Consortium. [Handelsman E](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Handelsman%20E%22), [Mendez H](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mendez%20H%22), [Birnbaum J](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Birnbaum%20J%22), [Eastwood B](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Eastwood%20B%22), [**Dieudonne A**](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dieudonne%20A%22). Associations of medically documented psychiatric diagnoses and risky health behaviors in highly active antiretroviral therapy- experienced perinatally HIV-infected youth. *AIDS Patient Care STDS* 2011 Aug;5(8):493-501.
* 40. Van Dyke RB, Patel K, Siberry GK, Burchett SK, Spector SA, Chernoff MC, Read JS, Mofenson LM, Seage GR 3rd; **Pediatric HIV/AIDS Cohort Study**. [Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes.](http://www.ncbi.nlm.nih.gov/pubmed/21407086) *J Acquir Immune Defic Syndr.*2011 Jun 1;57(2):165-73
* 41. Kapetanovic S, Leister E, Nichols S, Miller T, Tassiopoulos K, Hazra R, Gelbard HA, Malee KM, Kammerer B, Mendez AJ, Williams PL, **Dieudonne A,** Bettica L, Adubato, S: Pediatric HIV/AIDS Cohort Study Team, Relationships between markers of vascular dysfunction and neurodevelopmental outcomes in perinatally HIV infected youth. *AIDS 2010* June 19;24910): 1481-9*.*
* 42. Siberry GK, Williams PL, Lujan-Zibermann J, Warshaw MG, Spector SA, Decker MD, Heckman BE, Demske EF, Read JS, jean-Philippe P, Kabat W, Nachman S, Oleske J, Bardequez A, **Dieudonne A,** Bettica L. Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents. *Pediatr Infect. Dis. J.* 2010 May;29(5):391-6.
* 43. Weinberg A, Huang S, Fenton T, Patterson-Bartlett J, Gona P, Read JS, Dankner WM, Nachman S; **IMPAACT P1008 Team.** (2009) Virologic and immunologic correlates with the magnitude of antibodyresponses to the responses to the hepatitis A vaccine in HIV infected children on highly active antiretroviral treatment. *J Acquire Immune Defic Syndr.* 2009 Sept 1;52(1):17-24.
* 44. Patel K, Ming X, Williams Pl, Robertson KR, Oleske JM, Seage 3rd , **International**

**Maternal Pediatric Adolescent AIDS clinical Trials 219/219C Study Team.** Impact of

HAART and CNS-penetratingantiretroviral regimens on HIV encephalopathy among

perinatally HIV-infected children and adolescents. *AIDS 2009* Sept. 10;23(14):1893-901.

* 45. Nachman SA, Chernoff M, Gona P, Van dyke RB, Dankner WM, Seage GR 3rd,

Oleske J, Williams, PL; **PACTG 219C Team.** Incidence of noninfectious condition in perinatally HIV- infected children and adolescents in the HAART era. *Arch pediatr Adolesc Med.* 2009 Apr.;163(4):364.

* 46. Cennimo D, **Dieudonne A.** Parvovirus B19 Infection. *Emedicine.mediscape.com/article*

*961063*-overview, Aug. 4, 2009

* 47. Williams SF, Keane-Tarchichi MH, Bettica L, **Dieudonne A,** Bardeguez AD. Pregnancy

Outcome in young women with perinatally acquired human immunodeficiency virus-1. *AMJ*

* *48.* Tasiopoulos K, Williams PL, Seage GR 3rd, Crain M, Oleske J, Farley J; **International**

**Maternal Pediatric Adolescent AIDS Clinical Trials 219C Team.** (2008) Association of

hypercholesterolemia incidence with antiretroviral treatment, including protease inhibitors. Among

perinatally HIV-infected children. *J Acquir Immune Defic Syndr. 2008 Apr 15;47(5):607-14*

* *49.*  Ch’ng, T.W., **Dieudonne, A**. Immune Reconstitution Inflammatory Syndrome associated

with progressive multifocal leukoencephalopathy in a perinatally acquired immunodeficiency virus-

infected young adult. *Pediatric Infectious Disease Journal; (2007) 26(11):1068-1070.*

* 50. Abzug, M.J., Pelton, S.I., Song, LY., Fenton, T., **Dieudonne, A.,** et al. Immunogenicity, safety, and predictors of response after a pneumococcal onjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. *Pediatric Infectious Disease Journal; (2006) 25(10):920-929.*
* 51. Ezeanolue, E.E., Wodi, P.A., Patel, R., **Dieudonne, A**., & Oleske, J.M. Sexual behaviors

and procreational intentions of adolescents and young adults with perinatally acquired human

immunodeficiency virus infection: experience of a urban tertiary center. *J Adoles Health; (2006)*

*38:719-25*

*.*

* 52. Kovacs, A., Montepiedra, G., Carey,V., Pahwa, S., Weinberg, A., Frenkel, L., et al.

Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced

or progressive HIV disease and complete or partial viral load response J Infect Dis; (2005) 192:296-

302

* 53. Brogly, S., Williams, P., Seage, G.R., Oleske, J.M., Van Dyke, R., McIntosh, K., for the

**PACTG 219 Team**. Antiretroviral treatment in pediatric HIV infection in the United States. *JAMA*;

(2005)293(18):2213-2220.

* 54. Pelton S, Stanley K, Yogev R, Fletcher CV, McIntosh K, et al. Switch from Ritonavir to indinavir in combination therapy for HIV-1-infected children. *Clin Infect Dis;* (2005)40:1181-7.
* 55. Winful-Acquaye, E., Holland, B., Dashefsky, B., **Dieudonne, A**., Swerdlow, J., Rothpletz-

Puglia, P. et al. Metabolic abnormalities in pediatric HIV patients on antiretroviral therapy – A clinic

experience. Submitted to *Pediatrics (2005).*

* 56 **Dieudonne, A**., Oleske, J.M., & Schwartz, R.A. Atypical mycobacterial infection.

*emedicine.medscape.com*; (2004) 4 (7), 1-17.

* 57. Krogstad, P., Lee, J., Johnson, G., Stanley, K., McNamara, J., Moye, J., et al. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir

for pretreated children infected with human immunodeficiency virus type 1. C*linical Infectious*

*Disease Journal; (2002)*34 (7), 991-1001

* 58. Wiznia, A., Stanley, K., Krogstad, P., Johnson, G., Lee, S., McNamara, J., et al**.** Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir or

ritonavir in stable antiretroviral therapy - experienced HIV-infected children: Week 24 results of a

randomized controlled trial - PACTG 377. *AIDS Res Hum Retroviruses; (2000)* 16 (12), 1113-1121.

* 59 Barbashina, V., Heller, D.S., Hameed, M., Albanese, E., Goldstein, M., Dashefsky, B.,et al. Splenic smooth-muscle tumors in children with acquired immunodeficiency syndrome: A report of

two cases of this unusual location with evidence of an association with Epstein-Barr virus. *Virchows Archive; (2000)* 436, 138-9.

* 60. McKinney, R., Johnson, G., Stanley, K., Yong, F., Keller, A., O’Donnell, K., et al. A

randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. *Journal of Pediatrics; (1998)*133, 500-8.

BOOKS, MONGRAMS, & CHAPTERS

1. **Dieudonne, A.,** McIntyre J.A., Fregonese, F., Giaquinto, C., Oleske, J*.(2008) HAART in HIV-infected children: one decade later.*(pp. 63-79)A Decade of HAART The development and Global Impact of Highly Active Antiretroviral Therapy. Oxford University Press.
2. **Dieudonne, A.**, & Oleske, J.M. (2004). *Pediatric human immunodeficiency virus infection.*  In S. Gorbach, J. Bartlett & N. Blacklow (Eds.), *Infectious Diseases* (3rd ed., pp. 1056-1088). Philadelphia: Lippincott Williams & Wilkins.
3. McSherry, G., **Dieudonne, A.**, & O’Hara, M. (1996). *Identification and management of HIV-infected infants and children in New Jersey: A practical protocol for New Jersey clinicians (*3rd ed.). Princeton: The Academy of Medicine of New Jersey.
4. **Dieudonne, A**. (1996). *Mycobacterium avium* complex in HIV-infected infants and adolescents. Medical CME Monograph Program. *Medical Word Communications,* 8-10.

ABSTRACTS:

1. Ch’ng, T.W., **Dieudonne, A.** (2008, February). *Clinical Significance of Neutropenia in HIV Infected*

*Children.* St. Jude PIDS Pediatric Diseases Research Conference, Memphis, TN (#7101)

2. [Patel K](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Patel%20K%22%5BAuthor%5D), [Hernán MA](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hern%C3%A1n%20MA%22%5BAuthor%5D), [Williams PL](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Williams%20PL%22%5BAuthor%5D), [Seeger JD](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Seeger%20JD%22%5BAuthor%5D), [McIntosh K](http://www.ncbi.nlm.nih.gov/pubmed?term=%22McIntosh%20K%22%5BAuthor%5D), [Dyke RB](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Dyke%20RB%22%5BAuthor%5D), [Seage GR 3rd](http://www.ncbi.nlm.nih.gov/pubmed?term=%22Seage%20GR%203rd%22%5BAuthor%5D); Pediatric AIDS

Clinical Trials Group 219/219C. *Study Team Long-term effects of highly active antiretroviral therapy*

*on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting*.

.

1. Shauna, F.W., Megan, H.K., Bettica, L., **Dieudonne, A.,** Bardeguez, A.(2007, August). *Adherence*

*Issues and Viral Suppression in Perinatally-Infected Pregnant Adolescents.* Oral presentation at the

Infectious Diseases Society for Obstetrics and Gynecology, Boston, MA (#361).

1. Williams, S., Keane, M., Bettica, L., **Dieudonne, A.,** Bardeguez, A. (2007, July). *Pregnancy and*

*Neonatal Outcomes of Perinatally-Infected HIV Adolescents and Young Adults.*  Poster presentation at

the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia

(#TUPEB112)

1. McConnell, M., Clark, H., Zorrilla, C., **Dieudonne, A.,** et al. (2005 July). *Pregnancy in Perinatally HIV infected youth.* 3rd. IAS Conference on HIV Pathogenesis and Treatment, Rio De Janeiro, Brazil (abstract# MOPELB9,5C01)
2. Wodi, P., Weglarz, M., Davison, C., Colabelli, N., **Dieudonne, A**., & Oleske, J.M. (2005, May).

*Congenital syphilis in a cohort of newborns at high risk of HIV infection: Experience of a Boarder*

*Baby Nursery.* Poster session @ the 2005 Pediatric Academic Societies Annual Meeting,

Washington, DC (#539).

1. Ezeanolue, E., Wodi, A.P., Patel, R., **Dieudonne, A**., & Oleske, J. (2005, March & May 2005).

*Sexual behavior and procreational intentions of adolescents with perinatally acquired human*

*immunodeficiency infection.* Presented at the Eastern Society for Pediatric Research Meeting,

Norwalk, CT. & the 2005 Pediatric Academic Societies’ Annual Meeting, Washington, DC (#542).

1. Patel, R., Palmeri, A., Ezeanolue, E., Wodi, A.P., Desposito, F., **Dieudonne, A**., & Oleske, J. (2005,

March May 2005). *Transmission rate of perinatally acquired HIV infection in newborns with and*

*without sickle cell hemoglobinopathy.* Presented at the Eastern Society for Pediatric Research Meeting,

Norwalk, CT; & the 2005 Pediatric Academic Societies’ Annual Meeting, Washington, DC (#552).

1. **Dieudonne, A**. (2000, July). *Anti-retroviral therapy and quality of life*. Oral session, XIII

International AIDS Conference, Durban, So. Africa.

1. Rothpletz-Puglia, P., Oleske, J., Boland, M., Banyai, J., D’Orlando, D., & **Dieudonne, A**. (1998,

June-July). *Preliminary results of a retrospective study of nutrition intervention strategies for HIV*

*infected infants and children*. Presented at the 12th World AIDS Conference, Geneva, Switzerland,

(42344).

1. Rothpletz-Puglia, P., Oleske, J.M., Boland, M., Banyai, J., D’Orlando, D., & **Dieudonne, A.** (1998, July). n*utritional assessment of an HIV-infected child in the United States.*

12**. Dieudonne, A.,** McSherry, G., Holland, B., & Oleske, J. (1997, May). *Clinical outcome and survival*

*time in a cohort of HIV-infected children with atypical mycobacterial infections* [abstract 697].

Presented at the Annual Meeting of the Society for Pediatric Research, Washington, DC.

13. Denny, T.N., Stein, D., Ince, L., Mui, T., **Dieudonne, A.**, & Oleske, J.M. (1994, May). *Quantitative*

*immunoflourescent measurements of surface receptors on immune* *subsets from HIV-infected*

*children*. Presented at the APS/SPR/APA Convention, Seattle, WA.

REVIEWS

None

**PATENTS HELD**

None

Appendix:

Invited Speaker at International/National Meetings

* 1. International

2nd & 3rd Conference on Global Strategies for the Prevention of HIV

Transmission from Mothers to Infants, Montreal Canada, September 1999 & Kampala Uganda, September 2001

#### XIII International AIDS Conference – Durban, So. Africa, July 2000

Medical Research Foundation – Port of Spain, Trinidad, December 2004

* 1. National: None